Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9335)
All Articles published online
|
Publishing Process of This Article
|
Apr 10, 2017 (publication date) through Apr 1, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105 [PMID: 28439491 DOI: 10.5306/wjco.v8.i2.100] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v8/i2/100.htm |
| Number | Citing Articles |
| 1 |
Soichi Matsumura, Taigo Kato, Yuma Kujime, Hiroaki Kitakaze, Kosuke Nakano, Sachiko Hongo, Iwao Yoshioka, Masayoshi Okumi, Norio Nonomura, Shingo Takada. Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab. BMC Urology 2023; 23(1) doi: 10.1186/s12894-023-01248-z
|
| 2 |
Guobin Chen, Xiaoying Xie, Meixia Wang, Xinkun Guo, Zhenzhen Zhang, Lan Zhang, Boheng Zhang. Prognostic Significance of Tumor Growth Rate (TGR) in Patients with Huge Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization. Current Oncology 2022; 29(2): 423 doi: 10.3390/curroncol29020038
|
| 3 |
Pawel Chrom, Maciej Kawecki, Rafal Stec, Lubomir Bodnar, Cezary Szczylik, Anna M. Czarnecka. Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. Medical Oncology 2018; 35(6) doi: 10.1007/s12032-018-1148-x
|
| 4 |
Li-na He, Xuanye Zhang, Haifeng Li, Tao Chen, Chen Chen, Yixin Zhou, Zuan Lin, Wei Du, Wenfeng Fang, Yunpeng Yang, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang. Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.621329
|
| 5 |
Anna M. Czarnecka, Anna Brodziak, Pawel Sobczuk, Cezary Dendek, Dominika Labochka, Jan Korniluk, Ewa Bartnik, Cezary Szczylik. Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-44226-y
|
| 6 |
Veronica Mollica, Matteo Rosellini, Stefano Brocchi, Francesco Galuppi, Alexandro Paccapelo, Valentina Tateo, Andrea Marchetti, Elisa Tassinari, Francesco Mantuano, Matteo Santoni, Francesco Massari. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma. Expert Review of Precision Medicine and Drug Development 2024; 9(1): 17 doi: 10.1080/23808993.2024.2330422
|
| 7 |
Candice Schwartz, Nicklas Pfanzelter, Timothy M. Kuzel. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non–Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. Clinical Genitourinary Cancer 2017; 15(5): e903 doi: 10.1016/j.clgc.2017.05.017
|
| 8 |
Teresa Alonso-Gordoa, Georgia Anguera, Mario Domínguez-Esteban, Òscar Reig, Hilario Martínez-Barros, Javier Molina-Cerrillo, Patricia Cruz, Pablo Maroto. Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies. Cancer Treatment Reviews 2025; : 102925 doi: 10.1016/j.ctrv.2025.102925
|
| 9 |
Marwan Ghosn, Joseph Kattan, Fadi El Karak, Hady Ghanem, Jamil Debs, Khaled Ibrahim, Ali Shamseddine. Renal cell carcinoma management: real-world practice and challenges at a national level. Future Oncology 2023; 19(12): 863 doi: 10.2217/fon-2021-1189
|
| 10 |
Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno Debets, Egbert F. Smit, Joachim G.J.V. Aerts. Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. ERJ Open Research 2019; 5(4): 00179-2019 doi: 10.1183/23120541.00179-2019
|
| 11 |
Melissa Bersanelli, Sebastiano Buti. Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. Therapeutic Advances in Medical Oncology 2017; 9(10): 627 doi: 10.1177/1758834017724314
|
| 12 |
Ehab Abdou, Ravi M. Pedapenki, Mohamed Abouagour, Abdul R. Zar, Emad Dawoud, Dalia Elshourbagy, Humaid O. Al-Shamsi, Enrique Grande. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Review of Anticancer Therapy 2020; 20(10): 831 doi: 10.1080/14737140.2020.1810572
|
| 13 |
M. Albertelli, E. Nazzari, S. Sciallero, F. Grillo, S. Morbelli, F. De Cian, G. Cittadini, E. Ambrosetti, A. Ciarmiello, D. Ferone. Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. Journal of Endocrinological Investigation 2017; 40(11): 1265 doi: 10.1007/s40618-017-0692-0
|